在严重的败血症期间,BDKRB1的激活会诱导中性粒细胞的CXCR2脱敏,并加剧疾病的严重程度
Raquel Duque do Nascimento Arifa1,2, Carolina Braga Resende Mascarenhas1, Lívia Caroline Resende Rossi1
1Laboratory of Microorganism-Host Interaction, Department of Microbiology, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil.
JCI insight
|December 8, 2025
概括
布拉迪基宁B1受体 (BDKRB1) 在败血症引起的中性粒细胞功能障碍中起着关键作用. 抑制BDKRB1可以改善细菌清除,并在败血症模型中增强抗生素疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 微生物学 微生物学
背景情况:
- 败血症涉及宿主对感染的反应失调,其中涉及金因和布拉迪基宁受体 (B1和B2),但尚未完全理解.
- B1受体 (BDKRB1) 和B2受体 (BDKRB2) 在败血症发病过程中的特定作用需要进一步阐明.
研究的目的:
- 研究布拉迪基宁B1和B2受体在败血症中的参与.
- 评估BDKRB1作为毒症的潜在治疗标.
主要方法:
- 使用了结刺 (CLP) 毒症小鼠模型.
- 野生型 (WT) 鼠与Bdkrb1-/-和Bdkrb2-/-淘汰赛小鼠进行比较.
- 分析了中性粒细胞的流入,细菌负载,CXCR2表达和P110γ上调.
- 研究了药理学BDKRB1抑制与伊米相结合的影响.
- 在用LPS和CXCL8刺激的人类中性粒细胞中检查了BDKRB1的表达和功能.
主要成果:
- 基因删除Bdkrb2并没有显著影响小鼠的败血症结果.
- 在CLP后,Bdkrb1-/-小鼠的死亡率和细菌负载降低,中性粒细胞的流入增加.
- 来自Bdkrb1-/-小鼠的中性粒细胞表现出恢复的CXCR2表达和减少的P110γ.
- 与单独使用抗生素相比,药理学BDKRB1抑制加上伊米佩内姆显著改善了生存率.
- 人类中性粒细胞显示了LPS诱导的BDKRB1上调;BDKRB1对抗性恢复了中性粒细胞迁移.
结论:
- 在败血症期间,BDKRB1是中性粒细胞功能障碍的关键调节器.
- 抑制BDKRB1增强了细菌清除,恢复了中性粒细胞迁移,并提高了抗生素治疗的疗效.
- BDKRB1代表了毒症管理的有前途的治疗标.
相关概念视频
NF-κB-dependent Signaling Pathway
9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.7K
GPCR Desensitization
7.9K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.9K
Receptor Downregulation in MVBs
2.7K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.7K
MAPK Signaling Cascades
7.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.8K


